Trademark: 90272631
Status Date
Thursday, November 2, 2023
Filing Date
Thursday, October 22, 2020
Published for Opposition
Tuesday, March 22, 2022
44 Providing medical information relating to therapies and treatments for epilepsy and central nervous system diseases and disorders
42 Pharmaceutical research and development services in the field of epilepsy and central nervous system diseases and disorders; conducting clinical trials for others for pharmaceutical preparations for the treatment and prevention of epilepsy and central nervous system disease and disorders; pharmaceutical research services and pharmaceutical product evaluation, namely, conducting post-authorization research for the marketing of pharmaceutical preparations for the treatment and prevention of epilepsy and central nervous system disease and disorders, and evaluating epidemiological results for treatments for epilepsy and central nervous system diseases and disorders; providing medical and scientific research information to patients and practitioners in the field of clinical trials, namely, as to the results of clinical trials; providing medical and scientific research information to patients and practitioners in the field of clinical trials, namely, as to the results of clinical trials pertaining to therapies and treatments for epilepsy and central nervous system diseases and disorders
Nov 4, 2023
Notice Of Approval Of Extension Request E-Mailed
Nov 2, 2023
Sou Extension 3 Granted
Nov 2, 2023
Sou Extension 3 Filed
Nov 2, 2023
Sou Teas Extension Received
May 18, 2023
Notice Of Approval Of Extension Request E-Mailed
May 16, 2023
Sou Extension 2 Granted
May 16, 2023
Sou Extension 2 Filed
May 16, 2023
Sou Teas Extension Received
Oct 18, 2022
Notice Of Approval Of Extension Request E-Mailed
Oct 14, 2022
Sou Extension 1 Granted
Oct 14, 2022
Sou Extension 1 Filed
Oct 14, 2022
Sou Teas Extension Received
May 17, 2022
Noa E-Mailed - Sou Required From Applicant
Mar 22, 2022
Official Gazette Publication Confirmation E-Mailed
Mar 22, 2022
Published For Opposition
Mar 2, 2022
Notification Of Notice Of Publication E-Mailed
Feb 14, 2022
Law Office Publication Review Completed
Feb 14, 2022
Assigned To Lie
Feb 11, 2022
Approved For Pub - Principal Register
Feb 10, 2022
Examiner's Amendment Entered
Feb 10, 2022
Notification Of Examiners Amendment E-Mailed
Feb 10, 2022
Examiners Amendment E-Mailed
Feb 10, 2022
Examiners Amendment -Written
Aug 12, 2021
Notification Of Final Refusal Emailed
Aug 12, 2021
Final Refusal E-Mailed
Aug 12, 2021
Final Refusal Written
Jun 22, 2021
Teas/Email Correspondence Entered
Jun 21, 2021
Correspondence Received In Law Office
Jun 21, 2021
Teas Response To Office Action Received
Dec 19, 2020
Notification Of Non-Final Action E-Mailed
Dec 19, 2020
Non-Final Action E-Mailed
Dec 19, 2020
Non-Final Action Written
Dec 15, 2020
Assigned To Examiner
Dec 12, 2020
New Application Office Supplied Data Entered
Oct 26, 2020
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
